News

13.07.20

New motor neurone disease treatment shows encouraging results

A new drug targeting the genetic cause of a rare form of motor neurone disease (MND) has shown promise during early research trials, which are being supported by the National Institute for Health Research (NIHR).

Published in the New England Journal of Medicine, the phase 1-2 study showed a new investigational drug tofersen to be safe and well-tolerated in people with a genetic form of MND.

Around 5,000 people in the UK have MND, a disorder which affects the nerves – or motor neurones – in the brain and spinal cord which form the connection between the nervous system and muscles, enabling movement of the body. In people with MND, the messages from the nerves gradually stop reaching the muscles, leading them to weaken, stiffen and eventually waste.

The progressive disease affects a patient’s ability to walk, talk, use their arms and hands, eat and breathe.

Superoxide dismutase 1, known as SOD1, is the first gene found to cause MND. Mutations in this gene in people with MND cause a normal enzyme to become toxic to nerve cells and cause progression of the disease.

A faulty SOD1 gene is the known cause in 2% of all MND patients and up to 20% of patients who have a family history of the disease.

The new trial, supported by the NIHR Sheffield Biomedical Research Centre, a partnership between the University of Sheffield’s Institute for Translational Neuroscience (SITraN) and the Sheffield Teaching Hospitals NHS Foundation Trust, showed that tofersen has the potential to reduce the levels of the toxic protein generated by the faulty SOD1 gene. Reducing levels of the protein will reduce damage in the nerve cells and help to slow the progression of symptoms.

Professor Dame Pamela Shaw, Director of SITraN, European Chief Investigator on the trial and Director of the NIHR Sheffield Biomedical Research Centre, said: “The rise of genetic screening in our clinic means that we can now identify the different genetic subtypes of MND, which is helping to enhance the research effort.

“It has been a real privilege to participate in this trial of the investigational drug tofersen here in Sheffield, and our patients have shown huge commitment in taking part, so it’s a step forward that the published results warrant additional study in a larger patient group.”

The next phase of the trial will continue to further explore the safety and efficacy of the investigational drug.

Comments

There are no comments. Why not be the first?

Add your comment

 

national health executive tv

more videos >

latest news

View all News

comment

NHS England dementia director prescribes rugby for mental health and dementia patients

23/09/2019NHS England dementia director prescribes rugby for mental health and dementia patients

Reason to celebrate as NHS says watching rugby can be good for your mental ... more >
Peter Kyle MP: It’s time to say thank you this Public Service Day

21/06/2019Peter Kyle MP: It’s time to say thank you this Public Service Day

Taking time to say thank you is one of the hidden pillars of a society. Bei... more >

editor's comment

26/06/2020Adapting and Innovating

Matt Roberts, National Health Executive Editorial Lead. NHE May/June 2020 Edition We’ve been through so much as a health sector and a society in recent months with coronavirus and nothing can take away from the loss and difficulties that we’ve faced but it vital we also don’t disregard the amazing efforts we’ve witnessed. Staff have gone above and beyond, whole hospitals and trusts have flexed virtually at will to meet demand and pressures and we’ve... read more >

last word

Haseeb Ahmad: ‘We all have a role to play in getting innovations quicker’

Haseeb Ahmad: ‘We all have a role to play in getting innovations quicker’

Haseeb Ahmad, president of the Association of the British Pharmaceutical Industry (ABPI), sits down with National Health Executive as part of our Last Word Q&A series. Would you talk us throu more > more last word articles >

interviews

Matt Hancock says GP recruitment is on the rise to support ‘bedrock of the NHS’

24/10/2019Matt Hancock says GP recruitment is on the rise to support ‘bedrock of the NHS’

Today, speaking at the Royal College of General Practitioners (RCGP) annual... more >

the scalpel's daily blog

Adopting intelligent automation technology in the health service

06/08/2020Adopting intelligent automation technology in the health service

Darren Atkins, Chief Technology Officer (Artificial Intelligence & Automation), East Suffolk and North Essex NHS Foundation Trust featured on Episode 11 of NHE’s Fin... more >
read more blog posts from 'the scalpel' >

healthcare events

events calendar

back

August 2020

forward
mon tue wed thu fri sat sun
27 28 29 30 31 1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31 1 2 3 4 5 6

featured articles

View all News